I noticed this on Twitter last night:
@JonInPGH im cummin for ya tommorow gumba!! #saucyriceballs pic.twitter.com/SETXGfhtpl
— sawcefella (@realsaucefella) June 7, 2022
Seems that
our friends who infest The Taste of Sicily in Palmyra
are squeezing out a few more seconds from their
Warhol-attributed 15 minutes of fame.
In case you didn't already know, our distasteful Sicilian friends were arranging for the sale of "H" and
"I" as Covid treatments and were snagged by the internet. ("H" is clever
code for hydroxychloroquine just as "I" is clever code for ivermectin - get it?)
I look forward to hearing what the latest spew is all about on Wendy's medical misinformation show.
Even if Pennsylvania ultimately decides not to press charges, our Palmyric Sicilians put peoples' health at risk and they should be ashamed of themselves for
it.
Whatever the content of the chat, it still doesn't change the fact that hydroxychloroquine and ivermectin are not treatments for Covid-19.
Ivermectin.
- New England Journal of Medicine:
Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19. - Journal of the American Medical Association:
In this randomized clinical trial of high-risk patients with mild to moderate COVID-19, ivermectin treatment during early illness did not prevent progression to severe disease. The study findings do not support the use of ivermectin for patients with COVID-19.
Hydroxychloroquine:
- Journal of the American Medical Association:
This randomized clinical trial found no clinical benefit to support the use of either hydroxychloroquine or lopinavir-ritonavir in an outpatient population. This adds to the growing evidence that these drugs should not be used for the treatment of COVID-19. While evidence emerges to evaluate these drugs as prophylaxis, as treatment for both outpatients and inpatients, hydroxychloroquine and lopinavir-ritonavir do not appear to confer any clinical benefit. These results might affect several countries deciding whether to continue to offer both drug regimens for ambulatory patients presenting with mild COVID-19. The successful completion of this trial also demonstrates that expedient trials of repurposed drugs can be completed in low-income settings even during a global health crisis such as the COVID-19 pandemic. - New England Journal of Medicine:
After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure.
"H" and "I" are not adequate treatments for Covid-19 and selling them as such puts the public's health at risk.
How many Pennsylvanians suffered from the coronavirus simply because they put their faith in Christine Mason?
That's the only question worth asking here.
